WHO-appointed Afrigen vaccine consortium looking beyond Covid-19

Loading player...
The MD of Cape Town-based Afrigen Biologics and Vaccines, Prof Petro Terblanche, chats to BizNews in the wake of an announcement by the WHO that its consortium will be one of six tech-transfer hubs established on the continent. These six hubs will be ramping up production of commercially viable vaccines to about one billion doses for the continent, but its focus also will also lie beyond the current pandemic. It will be supporting efforts to increase Covid-19 vaccination rates in Africa, currently as low as 11% having received a single dose. Terblanche says they have created a platform that will allow them to manufacture vaccines for other diseases like HIV/Aids, TB, influenza, and ebola. Learn more about your ad choices. Visit megaphone.fm/adchoices
22 Feb 2022 9AM English South Africa Investing · Business News

Other recent episodes

Jacques Broodryk - AfriForum goes after the elusive Guptas…

AfriForum has asked the National Director of Public Prosecutions, Advocate Andy Mothibi, for an urgent update on the much delayed extradition of the Guptas who allegedly benefited from State Capture to the tune of between R50 and R70 billion. In this interview with Chris Steyn, Jacques Broodryk, AfriForum’s Chief Spokesperson:…
21 May 5AM 9 min

BN Daybreak - Thu 21 May 2026: Nvidia; SpaceX; Anthropic; Fed Hikes; Oil Shock; SA Infrastructure; Hartley on BRICS

In today's BizNews Daybreak, Nvidia delivers an upbeat sales forecast and multi-billion-dollar buyback plan, while SpaceX prepares for the world’s largest ever IPO. Meanwhile, Anthropic reports surging Claude revenue, and Fed minutes signal potential interest rate hikes. In global affairs, Middle East tensions cause oil market volatility, raising economic risks…
20 May 11PM 12 min

George Glynos - The Rand's Reckoning

The South African rand looks resilient - but George Glynos warns that appearances are dangerously deceiving. In this interview with Irakli, ETM Analytics Co-Founder and Head of Research lays out exactly why the risks are building asymmetrically against the rand - and why complacency could prove costly. On the scale…
20 May 10AM 11 min